Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 14

recruiting
3 968
countries
28
conditions
2 103

529 trials match your criteria

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Fallopian tube cancer+5

Recruiting

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Prostate cancer metastatic

Recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Hepatocellular carcinoma

Recruiting

Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Hormone-refractory prostate cancer

Recruiting

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Triple negative breast cancer+4

Recruiting

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Acute graft versus host disease

Recruiting

Study on Mesenchymal Stromal Cells (MC0518) for Treating Steroid-Resistant Acute Graft Versus Host Disease in Adults and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Everolimus

Persistent corneal epithelial defect

Recruiting

Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lufepirsen

Non-Hodgkin's lymphoma

Recruiting

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cyclophosphamide

Squamous cell carcinoma of head and neck

Recruiting

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

B-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tocilizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.